The Hindu Business Line  Mar 21  Comment 
Natco Pharma and the University of Hyderabad (UoH) have signed an MoU to carry out advance research in the areas of pharmaceutical importance. The focus areas will be discovery of novel drugs, dev...
The Hindu Business Line  Mar 21  Comment 
The Hindu Business Line  Mar 8  Comment 
In a significant ruling for generic drug companies, the Delhi High Court has allowed Hyderabad-based Natco to export its version of Bayer’s patented drug sorafenib tosylate for experimental purposes.
The Economic Times  Feb 28  Comment 
The report says that while there is room for a Blue Sky scenario in NPL once again, a probability discussed later in this report, it is not enough to assign a Buy rating to the stock.
The Economic Times  Feb 14  Comment 
Consolidated total income from operations rose to Rs 679.01 crore for the quarter as against Rs 288.09 crore a year ago.
The Economic Times  Feb 1  Comment 
“The share price fairly reflects upside from Copaxone 40 mg and approval remains a hurdle,“ said Nimish Mehta, founder director at ResearchDelta Advisors.
The Hindu Business Line  Jan 31  Comment 
Natco Pharma said a US District Court has ruled in favour of its marketing partner Mylan by invalidating Israel-based Teva Pharmaceuticals’ patents related to multiple sclerosis drug Copaxone 40 mg/m...
The Hindu Business Line  Jan 25  Comment 
Natco Pharma on Wednesday said it has been handed six observations by the US Food and Drug Administration for its facility at Kothur, near Hyderabad. The observations follow an inspection of the facil...
The Hindu Business Line  Jan 6  Comment 
Natco Pharma Ltd today said following the approval from US Food and Drug Administration for its generic version of Bendamustine Hydrochloride powder for injection, 25 mg/Vial and 100 mg/Vial (Singe—D...
The Hindu Business Line  Jan 2  Comment 
Natco Pharma today announced the launch of the first generic version of Sofosbuvir 400mg/Velpatasvir 100 mg fixed dose combination in Nepal. Sofosbuvir 400mg/Velpatasvir 100 mg fixed dose combinatio...
The Economic Times  Dec 30  Comment 
Buy Natco Pharma Ltd. with a target of Rs 750. The stock, Kotak Securities believes will continue to trade at higher multiples given the events lined up over the next 6-12 months.



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki